拉考沙胺联合吡仑帕奈添加治疗儿童难治性局灶性癫痫合并骨髓增生异常综合征一例并文献复习_Journal of Epilepsy

Authors：

 黄玲玲 ¹ , 吴正玉 ¹ , 刘程桃 ² , 孟丽萍 ¹ , 涂松济 ¹ , 储金华 ¹

1. ;
2. ;

Corresponding author：

黄玲玲, Email: huanglingling803@sohu.com

Keywords：

拉考沙胺; 吡仑帕奈; 儿童; 局灶性癫痫; 骨髓增生异常综合征

DOI：

10.7507/2096-0247.202406003

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 黄玲玲, 吴正玉, 刘程桃, 孟丽萍, 涂松济, 储金华. 拉考沙胺联合吡仑帕奈添加治疗儿童难治性局灶性癫痫合并骨髓增生异常综合征一例并文献复习. Journal of Epilepsy, 2024, 10(5): 449-453. doi: 10.7507/2096-0247.202406003 Copy

1.	Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 2010, 51(6): 1069-1077.
2.	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl), 2022, 135(5): 584-590.
3.	Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities. Nat Rev Clin Oncol, 2018, 15(1): 47-62.
4.	McCune JS, Wang T, Bo-Subait K, et al. Association of antiepileptic medications with outcomes after allogeneic hematopoietic cell transplantation with busulfan/cyslophosphamide conditioning. Biol Blood Marrow Transplant, 2019, 25(7): 1424-1431.
5.	Adès L, Duployez N, Guerci-Bresler A, et al. A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. Br J Haematol, 2022, 198(3): 535-544.
6.	Fukuyama T, Tanaka M, Nakazawa Y, et al. Prophylactic treatment for hypertension and seizure in a case of allo-geneic hematopoietic stem cell transplantation after posterior reversible encephalopathy syndrome. Pediatr Transplant, 2011, 15(8): E169-E173.
7.	唐静, 刘清扬, 林京玉, 等. 丙戊酸相关血液系统不良反应严重程度的相关因素分析. 实用药物与临床2020, 23(5): 466-470.
8.	Danese E, Montagnana M, Favaloro EJ, et al. Drug-induced thrombocytopenia: mechanisms and laboratory diagnostics. Semin Thromb Hemost, 2020, 46(3): 264-274.
9.	梁栋, 罗莉, 程均祥. 左乙拉西坦不良反应分析. 中国药物警讯, 2023, 20(9): 1054-1059.
10.	中华医学会血液学分会. 骨髓增生异常综合征中国诊断与治疗指南(2019年版). 中华血液学杂志, 2019, 40(2): 89-97.
11.	Lin CY, Chang CW, Tseng WJ, et al. Therapeutic drug monitoring of perampanel: clinical utility and impact of co-medication on pharmacokinetic variability. Heliyon, 2024, 10(1): e23962.
12.	Yang C, Liu Z, Peng Y, et al. Effectiveness and safety of Lacosamide therapy for children with focal epilepsy: a real world study. Front Pharmacol, 2023, 14: 1186786.
13.	Majid O, Laurenza A, Ferry J, et al. Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials. Br J Clin Pharmacol. 2016, 82(2): 422–430.
14.	De Liso P, Vigevano F, Specchio N, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-an Italian observational multicenter study. Epilepsy Res, 2016, 127: 93-100.
15.	陈国锋, 李国铭, 柯钟灵, 等. 吡仑帕奈在2~12岁儿童药物难治性癫痫添加治疗中的疗效观察. 中华实用儿科临床杂志, 2022, 37(3): 182-185.
16.	Zhao T, Li HJ, Feng JR, et al. Efficacy, tolerability, and safety of treatment with Perampanel in Pediatric patients with epilepsy aged ≥4 years: a real-life observational study. Journal of Child Neurology, 2023, 38: 414-421.
17.	姜玉武, 王艺, 钟建民, 等. 拉考沙胺添加治疗在中国儿童局灶性癫痫发作中的安全性与有效性─一项全球多中心单臂研究期中分析. 中华实用儿科临床杂志, 2023, 38(11): 850-856.
18.	Farkas V, Steinborn B, Flamini JR, et al. Efficacy and tolarebility of adjunctive Lacosamide in pediatric patients with focal seizures. Neurology, 2019, 93(12): e1212-e1226.
19.	Mohammadi T, Nasiri J, Ghazavi MR, et al. Efficacy of Lacosamide add-on therapy on refractory focal epilepsies in children and adolesecnts: an open-label clinical trial. J Res Pharm Pract, 2022, 11(3): 109-115.
20.	Ferreira JA, Le Pichon JB, Abdelmoity AT, et al. Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures – an open-label trial. Seizure. 2019, 71: 166–173.
21.	Farkas MK, Beller C, Bozorg A, et al. Safety and tolerability of short-term infusions of intravenous lacosamide in pediatric patients with epilepsy: an open-label, phase 2/3 trial. Epilepsia Open, 2023, 8(1): 146-153.
22.	Lattanzi S, Trinka E, Zaccara G, et al. Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis. Drugs, 2022, 82(2): 199-218.
23.	肖潇, 汤继宏, 张兵兵, 等. 拉考沙胺及吡仑帕奈添加治疗FIRES2例报告及文献复习. 甘肃医药, 2023, 42(1): 91-93+96.

1. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 2010, 51(6): 1069-1077.
2. Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl), 2022, 135(5): 584-590.
3. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities. Nat Rev Clin Oncol, 2018, 15(1): 47-62.
4. McCune JS, Wang T, Bo-Subait K, et al. Association of antiepileptic medications with outcomes after allogeneic hematopoietic cell transplantation with busulfan/cyslophosphamide conditioning. Biol Blood Marrow Transplant, 2019, 25(7): 1424-1431.
5. Adès L, Duployez N, Guerci-Bresler A, et al. A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. Br J Haematol, 2022, 198(3): 535-544.
6. Fukuyama T, Tanaka M, Nakazawa Y, et al. Prophylactic treatment for hypertension and seizure in a case of allo-geneic hematopoietic stem cell transplantation after posterior reversible encephalopathy syndrome. Pediatr Transplant, 2011, 15(8): E169-E173.
7. 唐静, 刘清扬, 林京玉, 等. 丙戊酸相关血液系统不良反应严重程度的相关因素分析. 实用药物与临床2020, 23(5): 466-470.
8. Danese E, Montagnana M, Favaloro EJ, et al. Drug-induced thrombocytopenia: mechanisms and laboratory diagnostics. Semin Thromb Hemost, 2020, 46(3): 264-274.
9. 梁栋, 罗莉, 程均祥. 左乙拉西坦不良反应分析. 中国药物警讯, 2023, 20(9): 1054-1059.
10. 中华医学会血液学分会. 骨髓增生异常综合征中国诊断与治疗指南(2019年版). 中华血液学杂志, 2019, 40(2): 89-97.
11. Lin CY, Chang CW, Tseng WJ, et al. Therapeutic drug monitoring of perampanel: clinical utility and impact of co-medication on pharmacokinetic variability. Heliyon, 2024, 10(1): e23962.
12. Yang C, Liu Z, Peng Y, et al. Effectiveness and safety of Lacosamide therapy for children with focal epilepsy: a real world study. Front Pharmacol, 2023, 14: 1186786.
13. Majid O, Laurenza A, Ferry J, et al. Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials. Br J Clin Pharmacol. 2016, 82(2): 422–430.
14. De Liso P, Vigevano F, Specchio N, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-an Italian observational multicenter study. Epilepsy Res, 2016, 127: 93-100.
15. 陈国锋, 李国铭, 柯钟灵, 等. 吡仑帕奈在2~12岁儿童药物难治性癫痫添加治疗中的疗效观察. 中华实用儿科临床杂志, 2022, 37(3): 182-185.
16. Zhao T, Li HJ, Feng JR, et al. Efficacy, tolerability, and safety of treatment with Perampanel in Pediatric patients with epilepsy aged ≥4 years: a real-life observational study. Journal of Child Neurology, 2023, 38: 414-421.
17. 姜玉武, 王艺, 钟建民, 等. 拉考沙胺添加治疗在中国儿童局灶性癫痫发作中的安全性与有效性─一项全球多中心单臂研究期中分析. 中华实用儿科临床杂志, 2023, 38(11): 850-856.
18. Farkas V, Steinborn B, Flamini JR, et al. Efficacy and tolarebility of adjunctive Lacosamide in pediatric patients with focal seizures. Neurology, 2019, 93(12): e1212-e1226.
19. Mohammadi T, Nasiri J, Ghazavi MR, et al. Efficacy of Lacosamide add-on therapy on refractory focal epilepsies in children and adolesecnts: an open-label clinical trial. J Res Pharm Pract, 2022, 11(3): 109-115.
20. Ferreira JA, Le Pichon JB, Abdelmoity AT, et al. Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures – an open-label trial. Seizure. 2019, 71: 166–173.
21. Farkas MK, Beller C, Bozorg A, et al. Safety and tolerability of short-term infusions of intravenous lacosamide in pediatric patients with epilepsy: an open-label, phase 2/3 trial. Epilepsia Open, 2023, 8(1): 146-153.
22. Lattanzi S, Trinka E, Zaccara G, et al. Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis. Drugs, 2022, 82(2): 199-218.
23. 肖潇, 汤继宏, 张兵兵, 等. 拉考沙胺及吡仑帕奈添加治疗FIRES2例报告及文献复习. 甘肃医药, 2023, 42(1): 91-93+96.

Previous Article
基于雨课堂的翻转课堂模式在长程脑电图教学实践中的探索
Next Article
DPAGT1基因变异相关先天性糖基化障碍一例并文献复习

Journal of Epilepsy

拉考沙胺联合吡仑帕奈添加治疗儿童难治性局灶性癫痫合并骨髓增生异常综合征一例并文献复习

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content